Testing Claudin 18.2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma: Current Status and Near‑Future Outlook
{{output}}
Claudin 18.2 (CLDN18.2) represents one of the newest biomarkers expected to enter routine testing in the near future and expanding the spectrum of available predictive markers. It is currently a clinically relevant predictor for adenocarcinomas of the stomach ... ...
